News
-
-
PRESS RELEASE
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million. Shareholders approved the takeover, with payment in cash and Mirum common stock, plus milestone payments -
-
-
-
-
-
-
-
PRESS RELEASE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2025 with key figures for the first six months of the 2025/2026 financial year
HBM Healthcare Investments posts CHF 96 million profit in H1 2025 despite currency challenges, driven by acquisitions and clinical successes. NAV and share price increase